Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sotac PharmaceuticalsNSE:SOTAC 50 Debt-to-Equity is 0.64 as of Mar. 2026, which is 43% below its 10-year median of 1.12. GuruFocus rates NSE:SOTAC with a GF Score™ of 50/100 and a GF Value™ of ₹142.95 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 814 Drug Manufacturers companies, Sotac Pharmaceuticals ranks worse than 76.66% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Sotac Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
NSE:SOTAC'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.55 Med: 1.12 Max: 6.87
Current: 0.64
During the past 7 years, the highest Debt-to-Equity Ratio of Sotac Pharmaceuticals was 6.87. The lowest was 0.55. And the median was 1.12.
NSE:SOTAC's Debt-to-Equity is ranked worse than 76.66% of 814
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs NSE:SOTAC: 0.64
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Sotac Pharmaceuticals Debt-to-Equity Related Terms
Sotac Pharmaceuticals Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Sotac Pharmaceuticals's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sotac Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotac Pharmaceuticals Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sotac Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Sotac Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sotac Pharmaceuticals (NSE:SOTAC) has a Debt-to-Equity of 0.64 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sotac Pharmaceuticals and its competitors. This is 43% below median its historical median of 1.12. Over the past decade, Sotac Pharmaceuticals' Debt-to-Equity has ranged from 0.55 to 6.87. According to the industry distribution chart, Sotac Pharmaceuticals ranks #624 out of 814 companies in the Drug Manufacturers industry, placing it in the top 76.7%.
Is Sotac Pharmaceuticals' Debt-to-Equity too high?
Sotac Pharmaceuticals' current Debt-to-Equity of 0.64 is 43% below median its 10-year median of 1.12. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 6.87. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Sotac Pharmaceuticals' value of 0.64 is 128.6% above this industry median. Based on the distribution chart, Sotac Pharmaceuticals ranks #624 out of 814 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sotac Pharmaceuticals has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sotac Pharmaceuticals' Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sotac Pharmaceuticals ranks #624 out of 814 companies for Debt-to-Equity. This places Sotac Pharmaceuticals in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Sotac Pharmaceuticals' value of 0.64 is 128.6% above this benchmark. Historically, Sotac Pharmaceuticals' own Debt-to-Equity has ranged from 0.55 to 6.87 over the past decade. While the company's 10-year median is 1.12 vs. the industry median of 0.28, Sotac Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sotac Pharmaceuticals's current Debt-to-Equity of 0.64 is 128.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sotac Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sotac Pharmaceuticals's current Debt-to-Equity is 0.64, which is 43% below median its own 10-year median of 1.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotac Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sotac Pharmaceuticals (NSE:SOTAC) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹142.95, compared to a current price of ₹90.05 — trading 37% below its estimated fair value. The current Debt-to-Equity is 0.64, which is 43% below median its 10-year median of 1.12 and 128.6% above the Drug Manufacturers industry median of 0.28. Sotac Pharmaceuticals' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Sotac Pharmaceuticals (NSE:SOTAC), the current Debt-to-Equity is 0.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotac Pharmaceuticals (NSE:SOTAC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotac Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹90.05 is trading 37% below its estimated GF Value™ of ₹142.95.
GuruFocus considers Sotac Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:SOTAC:
Debt-to-Equity: 0.64 (43% below median its 10-year median of 1.12)
GF Value™: ₹142.95 vs. price of ₹90.05 (37% below fair value)
Industry Position: 128.6% above the Drug Manufacturers median (#624 of 814)
No single metric tells the full story. See the NSE:SOTAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotac Pharmaceuticals Ltd operates chiefly in pharmaceutical manufacturing, serving a broad range of therapeutic segments including anti-diabetic, anti-psychotic, vitamins and minerals, anti-cold, anti-allergic, derma products, antacids, anti-ulcerants, cardiac, analgesic, anti-bacterial, anti-fungal, and more. The company manufactures tablets, capsules, syrups, and external preparations under contract manufacturing and loan licensing agreements, for domestic and international markets. Its clients include notable pharmaceutical marketers such as Cadila Pharma and Viatris. Revenue is distributed between domestic pharmaceutical product sales and international exports, supporting scalable growth across geographies.
50GF Score
Get the complete analysis for NSE:SOTAC
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SOTAC has been successfully added to your 
